logo
Explore dividend stocks

Altimmune, Inc

Add to watchlist
€9.95
Last updated:04/19/2021
3G0: F
Altimmune, Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against C… Show more

Dividend yield
-

Average yield for past twelve months.

P/E ratio
-

Payout ratio
-
Yearly

of earnings is used as dividends.

CASH payout ratio

Last quarter

Become our supporter to unlock all data!
Stock volatility (Beta)
past 12 months

Become our supporter to unlock all data!
Company debt level

Become our supporter to unlock all data!
3G0 dividends
Payout frequency
Unknown
Latest ex-date
01/20/2017
3y growth
Unknown
5y growth
Unknown
Company results
Quarterly
Annual
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
-46.42539M
-39.171152M
+15.63%
-20.520131M
+47.61%
-49.044477M
-139.01%
Cashflow
Sum up money going in and out company
-20.214079M
-9.388908M
+53.55%
-9.601997M
-2.27%
-34.436636M
-258.64%
Total liabilities
All combined debts and obligations
14.35261M
6.437976M
-55.14%
8.537874M
+32.62%
19.23889M
+125.34%
Company profile
CEO
Dr. Vipin K. Garg
Market capitalization
Small (0.37B)